Over the past few weeks, Abingdon Health has written some case studies on how they approach the development of both qualitative and quantitative lateral flow immunoassays (LFIA).
The following case studies were launched as part of Abingdon Health's Complete Integrated Solutions campaign, whereby Abingdon Health offers insight into the benefits of using one partner for lateral flow assay development and manufacture.
Rapid quantification of kappa and lambda free light chains with lateral flow technology
In this case study, we highlight the process in which Abingdon Health launched Seralite®– FLC, a rapid quantitative lateral flow test for haematology oncology. The test quantifies kappa and lambda free light chains in serum and is used as an aid for diagnosing and monitoring patients with suspected multiple myeloma, a rare blood cancer.
Helping to identify a significant problem in the dairy industry with lateral flow technology
Abingdon Health was awarded an Innovate UK grant to develop a multiplexed on-farm rapid test to identify a milk production affecting disease in cattle, mastitis. In this case study, we document the process our assay development specialists will take in bringing this important multiplexed rapid test to market.
Helping to fight devastating plant diseases with lateral flow technology
Abingdon Health has had a range of plant disease diagnostic products on the market for many years. In the following case study, Abingdon Health explains how this product, Pocket Diagnostic®, was developed and what path its development took.
Pocket Diagnostic® detects a number of important pathogens including a number of Phytophthora species such as; P. infestans, which was responsible for the Irish Potato Famine, and is still prevalent today, and P. ramorum, also known as Ramorum Blight or Sudden Oak Death, which has devastated the forestry industry in the UK, Northern Europe and North America for many years.